Nektar TherapeuticsNKTRNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -0.08% | +22.15% | -51.66% | -52.42% | -51.13% |
| Gross Profit Growth | +68.10% | +27.68% | -20.18% | -18.72% | -40.12% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.90% | +9.79% | +8.31% | +1.19% | +0.98% |
| Weighted Average Shares Diluted Growth | +9.90% | +11.81% | +8.31% | +1.19% | +0.98% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -38.10% | -28.55% | -68.45% | -53.40% | -39.28% |
| Inventory Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Asset Growth | -30.36% | -23.66% | -35.29% | -39.55% | -2.15% |
| Book Value per Share Growth | -72.09% | -57.76% | -89.99% | +0.00% | +72.36% |
| Debt Growth | -10.74% | -12.92% | -12.05% | -56.21% | -15.10% |
| R&D Expense Growth | +45.54% | -4.00% | +11.21% | +0.55% | -22.21% |
| SG&A Expenses Growth | -10.36% | -1.07% | +20.83% | -16.76% | -15.23% |